Summary: Axsome Therapeutics’ Q1 2024 report highlights advancements in its sleep medicine pipeline, with positive phase 3 results for AXS-12 in narcolepsy treatment and revenue …
Axsome Presents Q1 Results, Advances in Sleep Medicine Pipeline
Sleep
RKI – Behavior – Topic sheet: Sleep
central message Loud KiGGS In Wave 2 (2014–2017), 81% of children and adolescents achieved the age-specific recommended sleep duration. In adolescence, the proportion of those …